Medicare Enrolled
Dr. Andrew Pham, MD
Hospitalist Physician · Whittier, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Pham from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pham?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Pham
Dr. Andrew Pham is a hospitalist physician in Whittier, CA, with 11 years of NPI registration. Based on federal Medicare data, Dr. Pham performed 7,436 Medicare services across 344 unique beneficiaries.
Between the years covered by Open Payments, Dr. Pham received a total of $41,715 from 75 pharmaceutical and/or device companies across 502 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hospitalist physician. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Pham is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 1% volume in CA
$41,715 industry payments
Medicare Practice Summary
Medicare Utilization ↗7,436
Medicare services
Top 1% in CA for hospitalist physician
344
Unique beneficiaries
$28
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~676 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 6,600 | $18 | $34 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
276 | $103 | $356 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
226 | $148 | $499 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
78 | $66 | $191 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
74 | $12 | $49 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
61 | $25 | $80 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
32 | $141 | $461 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
24 | $145 | $528 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
19 | $33 | $50 |
| New patient office visit, complex (60-74 min) | 17 | $188 | $610 |
| Flu vaccine, quadrivalent A flu shot containing four strains of the influenza virus to help prevent seasonal influenza infection. |
15 | $76 | $153 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
14 | $106 | $414 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$41,715
Total received (2018-2024)
Avg $5,959/year across 7 years
Top 1% in CA for hospitalist physician
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
75
Companies
502
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$28,201 (67.6%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,281 (31.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$233 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,660
2023
$10,190
2022
$8,908
2021
$11,772
2020
$1,266
2019
$3,092
2018
$1,827
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$2,292
Merck Sharp & Dohme LLC
$302
Janssen Biotech, Inc.
$231
GlaxoSmithKline, LLC.
$224
Novartis Pharmaceuticals Corporation
$205
Takeda Pharmaceuticals U.S.A., Inc.
$156
JAZZ PHARMACEUTICALS INC.
$135
PFIZER INC.
$130
Aveo Pharmaceuticals, Inc.
$93
Astellas Pharma US Inc
$90
TAIHO ONCOLOGY, INC.
$56
Ipsen Biopharmaceuticals, Inc
$56
Daiichi Sankyo Inc.
$54
Tempus AI, Inc
$50
Incyte Corporation
$48
ABBVIE INC.
$48
Bayer Healthcare Pharmaceuticals Inc.
$46
Celgene Corporation
$43
Exelixis Inc.
$36
Novocure Inc.
$35
Genmab U.S., Inc.
$35
Myriad Genetic Laboratories, Inc.
$34
Gilead Sciences, Inc.
$33
PUMA BIOTECHNOLOGY, INC.
$29
SpringWorks Therapeutics, Inc.
$28
EMD Serono, Inc.
$26
GENZYME CORPORATION
$26
ARRAY BIOPHARMA INC
$25
Deciphera Pharmaceuticals Inc.
$24
Eisai Inc.
$24
Kite Pharma, Inc.
$23
Lilly USA, LLC
$16
Janssen Scientific Affairs, LLC
$7
Top 3 companies account for 60.6% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$20,929
Incyte Corporation
$4,770
GlaxoSmithKline, LLC.
$3,083
Bayer HealthCare Pharmaceuticals Inc.
$1,198
Amgen Inc.
$1,070
Merck Sharp & Dohme Corporation
$830
Genentech USA, Inc.
$639
E.R. Squibb & Sons, L.L.C.
$593
Pharmacyclics LLC, An AbbVie Company
$583
Gilead Sciences, Inc.
$548
Seagen Inc.
$450
GENZYME CORPORATION
$433
Janssen Biotech, Inc.
$421
Novartis Pharmaceuticals Corporation
$415
PFIZER INC.
$358
Merck Sharp & Dohme LLC
$341
Alexion Pharmaceuticals, Inc.
$297
Apellis Pharmaceuticals, Inc.
$250
Daiichi Sankyo Inc.
$240
Astellas Pharma US Inc
$233
Exelixis Inc.
$223
PUMA BIOTECHNOLOGY, INC.
$217
Novocure Inc.
$201
Lilly USA, LLC
$194
Myriad Genetic Laboratories, Inc.
$188
Takeda Pharmaceuticals U.S.A., Inc.
$181
Foundation Medicine, Inc.
$172
Kite Pharma, Inc.
$168
Pharmacyclics LLC, an AbbVie Company
$149
JAZZ PHARMACEUTICALS INC.
$135
Coherus Biosciences Inc.
$125
Karyopharm Therapeutics Inc.
$118
Acrotech Biopharma Inc.
$108
Blueprint Medicines Corporation
$104
ABBVIE INC.
$96
Eisai Inc.
$94
Aveo Pharmaceuticals, Inc.
$93
Ipsen Biopharmaceuticals, Inc
$92
ADC Therapeutics America, Inc.
$89
EMD Serono, Inc.
$89
Celgene Corporation
$89
Myovant Sciences Inc.
$67
Dendreon Pharmaceuticals LLC
$67
Seattle Genetics, Inc.
$66
BeiGene USA, Inc.
$62
Acrotech Biopharma LLC
$60
TAIHO ONCOLOGY, INC.
$56
Tempus AI, Inc
$50
Lexicon Pharmaceuticals, Inc.
$47
Bayer Healthcare Pharmaceuticals Inc.
$46
Puma Biotechnology, Inc.
$46
G1 Therapeutics, Inc.
$40
MorphoSys, US Inc.
$39
Genmab U.S., Inc.
$35
Bioventus LLC
$29
SpringWorks Therapeutics, Inc.
$28
ARRAY BIOPHARMA INC
$25
AbbVie Inc.
$25
AVEO Pharmaceuticals, Inc.
$25
TOLMAR Pharmaceuticals, Inc.
$25
Deciphera Pharmaceuticals Inc.
$24
EISAI INC.
$23
Agios Pharmaceuticals, Inc.
$23
Regeneron Healthcare Solutions, Inc.
$21
Sun Pharmaceutical Industries Inc.
$20
Taiho Oncology, Inc.
$20
TG THERAPEUTICS, INC.
$20
Global Blood Therapeutics, Inc.
$20
Otsuka America Pharmaceutical, Inc.
$19
Dova Pharmaceuticals
$18
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Clovis Oncology, Inc.
$15
Array BioPharma Inc.
$14
Advanced Accelerator Applications
$13
Janssen Scientific Affairs, LLC
$7
Top 3 companies account for 69.0% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Avastin · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · Braftovi · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · EMEND · EMPLICITI · ENHERTU · ERLEADA · EXKIVITY · Empaveli · Enhertu · Epkinly · FOLOTYN · FOTIVDA · FOUNDATIONONE · FOUNDATIONONE CDX · FOUNDATIONONE LIQUID CDX · FRUZAQLA · Fabhalta · GAVRETO · GELSYN-3 · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MVASI · MYLOTARG · MYRISK · NERLYNX · NINLARO · NOXAFIL · NUCALA · Neulasta · Nexavar · Nplate · Nubeqa · OGSIVEO · OPDIVO · ORGOVYX · OXBRYTA · Onivyde · Optune Lua (NovoTTF-200T) · PADCEV · PEMAZYRE · PIQRAY · PREVYMIS · PROMACTA · PROVENGE · Pomalyst · QINLOCK · REBLOZYL · Rituxan · Rubraca · SAMSCA · SARCLISA · SOMATULINE DEPOT · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TIBSOVO · TIVDAK · Trodelvy · UKONIQ · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · Vectibix · Vitrakvi · XGEVA · XPOVIO · XT CDX · XTANDI · Xermelo · YERVOY · YONSA · Yescarta · ZEJULA · ZEPZELCA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (68%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 1% for hospitalist physician in CA.
Geographic Context
Hospitalist physicians within 10 mi
283
Per 100K population
2.9
County median income
$87,760
Nearest hospital
PIH HEALTH HOSPITAL-WHITTIER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Pham is a mixed practice specialist, with above-average Medicare volume (top 1% in CA), with consulting-driven industry engagement in the top 1% of CA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Pham experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Pham performed 6,600 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pham receive payments from pharmaceutical companies?
Yes. Dr. Pham received a total of $41,715 from 75 companies across 502 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pham's costs compare to other hospitalist physicians in Whittier?
Dr. Pham's average Medicare payment per service is $28. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pham) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hospitalist Physicians in Whittier
Browse hospitalist physicians in Whittier ranked by procedure volume and transparency data.
Highest volume
Top Hospitalist Physicians in CA
Hospitalist physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hospitalist Physicians in CA
Which CA hospitalist physicians receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology